CN1266475C - 一种用于诊断早期卵巢癌的四粘蛋白酶联免疫检测试剂盒 - Google Patents
一种用于诊断早期卵巢癌的四粘蛋白酶联免疫检测试剂盒 Download PDFInfo
- Publication number
- CN1266475C CN1266475C CN 03136488 CN03136488A CN1266475C CN 1266475 C CN1266475 C CN 1266475C CN 03136488 CN03136488 CN 03136488 CN 03136488 A CN03136488 A CN 03136488A CN 1266475 C CN1266475 C CN 1266475C
- Authority
- CN
- China
- Prior art keywords
- kit
- polyclonal antibody
- oophoroma
- plate
- ovarian cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002965 ELISA Methods 0.000 title claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 7
- 102000015728 Mucins Human genes 0.000 title 1
- 108010063954 Mucins Proteins 0.000 title 1
- 238000003908 quality control method Methods 0.000 claims abstract description 29
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 24
- 238000002360 preparation method Methods 0.000 claims abstract description 22
- 108090000790 Enzymes Proteins 0.000 claims abstract description 15
- 102000004190 Enzymes Human genes 0.000 claims abstract description 15
- 206010033128 Ovarian cancer Diseases 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 27
- 238000006243 chemical reaction Methods 0.000 claims description 19
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 17
- 239000007853 buffer solution Substances 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 14
- 238000004140 cleaning Methods 0.000 claims description 12
- 206010003445 Ascites Diseases 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 238000010790 dilution Methods 0.000 claims description 8
- 239000012895 dilution Substances 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 239000000758 substrate Substances 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 5
- 230000001900 immune effect Effects 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 238000006911 enzymatic reaction Methods 0.000 claims description 4
- 238000004255 ion exchange chromatography Methods 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- 238000012044 lysine affinity chromatography Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000001514 detection method Methods 0.000 abstract description 14
- 238000003745 diagnosis Methods 0.000 abstract description 8
- 238000004393 prognosis Methods 0.000 abstract description 4
- 238000011156 evaluation Methods 0.000 abstract description 3
- 238000012544 monitoring process Methods 0.000 abstract description 3
- 238000002512 chemotherapy Methods 0.000 abstract description 2
- 239000012474 protein marker Substances 0.000 abstract description 2
- 101000972286 Homo sapiens Mucin-4 Proteins 0.000 abstract 2
- 102100022693 Mucin-4 Human genes 0.000 abstract 2
- 238000008157 ELISA kit Methods 0.000 abstract 1
- 239000012752 auxiliary agent Substances 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 description 19
- 238000012360 testing method Methods 0.000 description 16
- 229940088598 enzyme Drugs 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 238000012856 packing Methods 0.000 description 9
- 238000004321 preservation Methods 0.000 description 9
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 7
- 238000013016 damping Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 238000004108 freeze drying Methods 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000003097 mucus Anatomy 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000006196 deacetylation Effects 0.000 description 3
- 238000003381 deacetylation reaction Methods 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 208000006379 syphilis Diseases 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 2
- 102100037362 Fibronectin Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102100024554 Tetranectin Human genes 0.000 description 2
- 108010079337 Tissue Polypeptide Antigen Proteins 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 241000726445 Viroids Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 108010013645 tetranectin Proteins 0.000 description 2
- HZTFKKZIUKAMKZ-ODZAUARKSA-N (z)-4-amino-4-oxobut-2-enoic acid;pyrrole-2,5-dione Chemical compound O=C1NC(=O)C=C1.NC(=O)\C=C/C(O)=O HZTFKKZIUKAMKZ-ODZAUARKSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 208000009849 Female Genital Neoplasms Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000003723 Smelting Methods 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- FSQQTNAZHBEJLS-UPHRSURJSA-N maleamic acid Chemical compound NC(=O)\C=C/C(O)=O FSQQTNAZHBEJLS-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000011248 postoperative chemotherapy Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03136488 CN1266475C (zh) | 2003-06-05 | 2003-06-05 | 一种用于诊断早期卵巢癌的四粘蛋白酶联免疫检测试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03136488 CN1266475C (zh) | 2003-06-05 | 2003-06-05 | 一种用于诊断早期卵巢癌的四粘蛋白酶联免疫检测试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1553190A CN1553190A (zh) | 2004-12-08 |
CN1266475C true CN1266475C (zh) | 2006-07-26 |
Family
ID=34323343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03136488 Expired - Fee Related CN1266475C (zh) | 2003-06-05 | 2003-06-05 | 一种用于诊断早期卵巢癌的四粘蛋白酶联免疫检测试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1266475C (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007081768A2 (en) * | 2006-01-04 | 2007-07-19 | Fujirebio America, Inc. | Use of he4 and other biochemical markers for assessment of ovarian cancers |
CN102707068B (zh) * | 2012-05-31 | 2015-03-18 | 北京大学 | 补体h因子用作甲基苯丙胺成瘾患者的基因表达产物中的应用 |
CN103983791A (zh) * | 2014-05-29 | 2014-08-13 | 深圳市柏明胜医疗器械有限公司 | 一种人ca125蛋白量子点标记的双夹心免疫分析检测试剂盒 |
CN111735949B (zh) * | 2020-07-17 | 2023-07-21 | 北京信诺卫康科技有限公司 | Wnt7a和CA125联合用作早期卵巢癌生物标志物以及试剂盒 |
CN111961723A (zh) * | 2020-07-17 | 2020-11-20 | 潘志文 | 用于早期卵巢癌诊断的无创检测的肿瘤标志物及试剂盒 |
CN113325178A (zh) * | 2021-05-27 | 2021-08-31 | 江苏省肿瘤医院 | 一种用于卵巢癌早期诊断及预后评估的检测试剂盒 |
-
2003
- 2003-06-05 CN CN 03136488 patent/CN1266475C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1553190A (zh) | 2004-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101738473B (zh) | 梅毒螺旋体抗体诊断试剂盒及其制备方法 | |
CN101029897A (zh) | 一种降钙素原测试试剂盒及其测试方法 | |
CN1793927A (zh) | 一种检测盐酸克伦特罗的试剂盒及其检测方法 | |
CN104090105A (zh) | 一种检测hev抗体的方法及试剂盒和该试剂盒的制备方法 | |
CN101833009A (zh) | 一种双抗体复合的视黄醇结合蛋白检测试剂盒 | |
CN103033624A (zh) | 一种人髓过氧化物酶化学发光免疫检测试剂盒 | |
CN1885039A (zh) | 小分子间接标记的双抗原夹心法测定丙型肝炎病毒总抗体 | |
CN103076455A (zh) | 快速定量检测血清淀粉样蛋白a试剂盒及其制备和应用 | |
CN104280437A (zh) | 一种β-肾上腺素受体激动剂多残留检测免疫传感器及其检测方法 | |
CN1266475C (zh) | 一种用于诊断早期卵巢癌的四粘蛋白酶联免疫检测试剂盒 | |
JP2014523525A (ja) | プロテオミクスに基づく、慢性副鼻腔炎の診断用検出方法 | |
CN101403752A (zh) | 一种加替沙星的化学发光酶联免疫检测试剂盒 | |
CN105938146A (zh) | 一种hbv表面抗体时间分辨免疫荧光检测试剂盒及其制备方法 | |
CN1712964A (zh) | 类风湿性关节炎特异性抗原性标志物及其应用 | |
CN113125753B (zh) | 一种用于检测尘螨组分特异性抗体的试剂盒 | |
CN105842464B (zh) | 基于上转换发光技术的联合定量检测uNGAL和uCr的装置及其制备方法 | |
CN110441293A (zh) | 一种基于蛋白活性保护的电化学发光传感器制备方法及应用 | |
CN102128937B (zh) | 用于脱敏治疗效果评价的过敏原特异性IgG4抗体检测试剂盒的制备方法 | |
Wang et al. | VKORC1 haplotypes influence the performance characteristics of PIVKAII for screening of hepatocellular carcinoma | |
CN107091925A (zh) | 一种检测牙周炎相关蛋白的抗体芯片及试剂盒 | |
CN1869702A (zh) | 肝炎与肝硬化的集成检测反应板和蛋白芯片试剂盒 | |
CN1188235A (zh) | 抗人iv型胶原蛋白酶联免疫定量测定试剂盒及制作方法 | |
CN1266476C (zh) | 用妊娠相关蛋白-a检测孕早期唐氏综合征的试剂盒 | |
CN1266478C (zh) | 用胰岛素生长因子结合蛋白-4水解酶检测急性冠状动脉综合征的试剂盒 | |
CN104280540A (zh) | β-肾上腺素受体激动剂多残留检测免疫传感器及其检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: STATE FAMILY PLANNING BIRTH DEFECT INTERVENTION E Free format text: FORMER OWNER: MA XU Effective date: 20080912 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20080912 Address after: Beijing City, Haidian District Dahui Temple No. 12 of the State Family Planning Commission birth defect intervention project technology center Patentee after: National Family Planning Commission birth defects intervention Engineering Technology Center Address before: Beijing City, Haidian District Dahui Temple No. 12 of the State Family Planning Commission birth defect intervention project technology center Patentee before: Ma Xu |
|
CI01 | Correction of invention patent gazette |
Correction item: Patentee Correct: National population and Family Planning Commission birth defects intervention Engineering Technology Center False: National Family Planning Commission birth defects intervention Engineering Technology Center Number: 43 Page: 1352 Volume: 24 |
|
ERR | Gazette correction |
Free format text: CORRECT: PATENTEE; FROM: STATE FAMILY PLANNING BIRTH DEFECT INTERVENTION ENGINEERING CENTER TO: BIRTH-DEFECT INTERVENTION PROJECT TECHNOLOGY CENTER, NATIONAL POPULATION AND FAMILY PLANNING COMMISSION OF P.R.CHINA |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20090327 Address after: Beijing City, Haidian District Dahui Temple No. 12 of the national population and Family Planning Commission birth defect intervention project technology center zip code: 100081 Co-patentee after: National Population and Family Planning Commission of China Patentee after: National population and Family Planning Commission birth defects intervention Engineering Technology Center Address before: Beijing City, Haidian District Dahui Temple No. 12 of the national population and Family Planning Commission birth defect intervention project technology center zip code: 100081 Patentee before: National population and Family Planning Commission birth defects intervention Engineering Technology Center |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060726 Termination date: 20170605 |